> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves J&J Varipulse Platform
- URL: https://www.fdaweb.com/fda-approves-j-j-varipulse-platform/
- Published: 2024-11-07T12:00:00.000Z
- Updated: 2026-09-14T14:46:25.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5158144

FDA has approved the Johnson & Johnson Varipulse pulse field ablation platform to treat atrial fibrillation. A company [statement](https://www.jnj.com/media-center/press-releases/johnson-johnson-medtech-receives-fda-approval-for-the-varipulse-pulsed-field-ablation-platform-for-the-treatment-of-atrial-fibrillation?ref=fdaweb.com#:~:text=Irvine%2C%20CA%20&) says Varipulse is the only pulse field ablation system in the U.S. fully integrated with the J&J CARTO 3 electro-anatomical mapping system, driving efficiency, reproducibility, and accuracy.

Approval was supported by the admIRE study in which 85% peak primary effectiveness, 12-month success, and minimal-to-no fluoroscopy were achieved, the statement says.

The company says the fully integrated platform includes the Varipulse catheter, Trupulse generator, and CARTO 3 mapping system Varipulse software.